Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haloprogin is a halogenated phenolic ether and topical antifungal drug formerly used to treat superficial fungal infections of the skin, such as tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete’s foot). It was marketed in 1% creams under several brand names. The mechanism of action is not fully understood but is thought to involve inhibition of oxygen uptake and disruption of fungal cell membrane structure and function, leading to fungicidal activity. Haloprogin was associated with a relatively high incidence of local side effects including irritation, burning, blistering, scaling, and itching. Due to these adverse effects and the availability of newer antifungals with better safety profiles, it has been discontinued in many markets including the United States[1][2][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haloprogin.